To reach the next value inflection
LicenseRx asset brief
New Anti-Influenza Virus Neuraminidase 9 (N9) Monoclonal Antibody – for Prevention or Treatment of H7N9 Influenza (Flu) A with Less Likelihood of Drug Resistance
Probability of Success
25% · grade C · Medium data confidence
Model PoS 25% (grade C, medium data confidence). Strongest signals: Data maturity, Indication pull. Biggest drag: IP position.
Data maturity (22%)
59
Preclinical; human data.
IP position (16%)
30
Protection lapsed or abandoned -- verify freedom to operate.
Modality feasibility (14%)
66
Biologic/antibody -- solid path but higher CMC burden.
Indication pull (14%)
75
Infectious Disease, Immunology -- active buyer appetite.
Competitive whitespace (12%)
86
Under-served segment; multi-modal differentiation.
Translational evidence (12%)
54
Public evidence mentions: human.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →